I am a nuclear medicine physician whose clinical interests focus on the use of positron emission tomography (PET) for diagnostic and molecular imaging. I also have special expertise in the care and management of patients who receive radiotargeted therapy, particularly for thyroid cancer.
I am Head of the Nuclear Medicine Research Laboratory. I am also a member of the Executive Council for the Molecular Pharmacology Program of the Sloan Kettering Institute. My research interests involve PET and targeted therapy in oncology. I have had a long-term interest in radiopharmaceuticals for oncologic applications in nuclear medicine and have been working in various aspects of PET since 1979.
Sponsored by the US Department of Energy and in collaboration with Radiochemistry/Cyclotron Core Facility head Ronald Finn, I led an effort to develop novel radiopharmaceuticals for implementation in research in both animals and humans. During the past ten years, this effort has resulted in the introduction of more than 40 new radionuclides and compounds for implementation in animal research here at Memorial Sloan Kettering.
Over the years, I have served on several government advisory committees. I chaired the Radioactive Drug Advisory Committee of the US Food and Drug Administration and was part of a team that developed the 21CFR361.1 Radioactive Drug Research Committee regulations. I am currently the principal investigator of several large grants from the DOE and the National Institutes of Health, including the grant that provides funding for Memorial Sloan Kettering’s Center for Multidisciplinary In Vivo Molecular Imaging in Cancer.
I have received a number of awards in nuclear medicine, including the Hevesy Award from both the Society of Nuclear Medicine (SNM) and the European Society of Nuclear Medicine, the Pendergrass Award and the Radiologic Researcher of the Year Award from the Radiological Society of North America, and the Wagner Lecture Award from the SNM. I have also received the Wiley Medal from the FDA, for distinguished service.
- Clinical Expertise: General Nuclear Medicine; Radiolabeled Antibodies for Tumor Imaging and Therapy; Positron Emission Tomography; Radioisotopic Therapy for Thyroid Cancer
- Languages Spoken: English
- Education: MD, University of Washington School of Medicine (Seattle)
- Residencies: Virginia Mason Hospital (Seattle)
- Fellowships: National Institutes of Health
- Board Certifications: Nuclear Medicine; Internal Medicine
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Co-Investigated by Steven M. Larson
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more